|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Durfee RA, Mohammed M and Luu HH: Review
of osteosarcoma and current management. Rheumatol Ther. 3:221–243.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marec-Berard P, Laurence V, Occean BV,
Ray-Coquard I, Linassier C, Corradini N, Collard O, Chaigneau L,
Cupissol D, Kerbrat P, et al: Methotrexate-Etoposide-ifosfamide
compared with doxorubicin-cisplatin-ifosfamide chemotherapy in
osteosarcoma treatment, patients aged 18-25 years. J Adolesc Young
Adult Oncol. 9:172–182. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moreno F, Cacciavillano W, Cipolla M,
Coirini M, Streitenberger P, Lopez Marti J, Palladino M, Morici M,
Onoratelli M, Drago G, et al: Childhood osteosarcoma: Incidence and
survival in argentina. report from the national pediatric cancer
registry, ROHA network 2000-2013. Pediatr Blood Cancer 64 2017.
|
|
6
|
Revon-Riviere G, Banavali S, Heississen L,
Gomez Garcia W, Abdolkarimi B, Vaithilingum M, Li CK, Leung PC,
Malik P, Pasquier E, et al: Metronomic chemotherapy for children in
low- and middle-income countries: Survey of current practices and
opinions of pediatric oncologists. J Glob Oncol. 5:1–8.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gyawali B, Bouche G, Crisp N and André N:
Challenges and opportunities for cancer clinical trials in low- and
middle-income countries. Nature Cancer. 1:142–145. 2020.
|
|
8
|
Bertolini F, Sukhatme VP and Bouche G:
Drug repurposing in oncology-patient and health systems
opportunities. Nat Rev Clin Oncol. 12:732–742. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pushpakom S, Iorio F, Eyers PA, Escott KJ,
Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et
al: Drug repurposing: Progress, challenges and recommendations. Nat
Rev Drug Discov. 18:41–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pantziarka P and Andre N: Editorial: Drug
repurposing. Front Med (Lausanne). 6(154)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Svensson PJ, Bergqvist PB, Juul KV and
Berntorp E: Desmopressin in treatment of haematological disorders
and in prevention of surgical bleeding. Blood Rev. 28:95–102.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kaufmann JE, Oksche A, Wollheim CB,
Gunther G, Rosenthal W and Vischer UM: Vasopressin-induced von
Willebrand factor secretion from endothelial cells involves V2
receptors and cAMP. J Clin Invest. 106:107–116. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Garona J, Pifano M, Pastrian MB, Gomez DE,
Ripoll GV and Alonso DF: Addition of vasopressin synthetic analogue
[V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth
inhibition and impairs metastatic spread in aggressive breast
tumour models. Clin Exp Metastasis. 33:589–600. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Garona J, Pifano M, Scursoni AM, Gomez DE,
Alonso DF and Ripoll GV: Insight into the effect of the vasopressin
analog desmopressin on lung colonization by mammary carcinoma cells
in BALB/c mice. Anticancer Res. 34:4761–4765. 2014.PubMed/NCBI
|
|
15
|
Weinberg RS, Grecco MO, Ferro GS,
Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna
E, Sánchez-Marull R, Frahm I, et al: A phase II dose-escalation
trial of perioperative desmopressin (1-desamino-8-d-arginine
vasopressin) in breast cancer patients. Springerplus.
4(428)2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pifano M, Garona J, Capobianco CS,
Gonzalez N, Alonso DF and Ripoll GV: Peptide agonists of
vasopressin V2 receptor reduce expression of neuroendocrine markers
and tumor growth in human lung and prostate tumor cells. Front
Oncol. 7(11)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pifano M, Garona J, Sobol NT, Alberto M,
Alonso DF and Ripoll GV: Search of vasopressin analogs with
antiproliferative activity on small-cell lung cancer: Drug design
based on two different approaches. Future Med Chem. 10:879–894.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ripoll GV, Garona J, Hermo GA, Gomez DE
and Alonso DF: Effects of the synthetic vasopressin analog
desmopressin in a mouse model of colon cancer. Anticancer Res.
30:5049–5054. 2010.PubMed/NCBI
|
|
19
|
Garona J, Sobol NT, Pifano M, Segatori VI,
Gomez DE, Ripoll GV and Alonso DF: Preclinical efficacy of [V4
Q5]dDAVP, a second generation vasopressin analog, on metastatic
spread and tumor-associated angiogenesis in colorectal cancer.
Cancer Res Treat. 51:438–450. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Terraube V, Pendu R, Baruch D, Gebbink MF,
Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of
tumor cells in von Willebrand factor-deficient mice. J Thromb
Haemost. 4:519–526. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mochizuki S, Soejima K, Shimoda M, Abe H,
Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on
carcinoma cell metastasis by cleavage of von Willebrand factor. J
Natl Cancer Inst. 104:906–922. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gragnano F, Sperlongano S, Golia E, Natale
F, Bianchi R, Crisci M, Fimiani F, Pariggiano I, Diana V, Carbone
A, et al: The role of von willebrand factor in vascular
inflammation: From pathogenesis to targeted therapy. Mediators
Inflamm. 2017(5620314)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Keegan BP, Akerman BL, Pequeux C and North
WG: Provasopressin expression by breast cancer cells: Implications
for growth and novel treatment strategies. Breast Cancer Res Treat.
95:265–277. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Garona J, Pifano M, Orlando UD, Pastrian
MB, Iannucci NB, Ortega HH, Podesta EJ, Gomez DE, Ripoll GV and
Alonso DF: The novel desmopressin analogue [V4Q5]dDAVP inhibits
angiogenesis, tumour growth and metastases in vasopressin type 2
receptor-expressing breast cancer models. Int J Oncol.
46:2335–2345. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sasaki H, Klotz LH, Sugar LM, Kiss A and
Venkateswaran V: A combination of desmopressin and docetaxel
inhibit cell proliferation and invasion mediated by urokinase-type
plasminogen activator (uPA) in human prostate cancer cells. Biochem
Biophys Res Commun. 464:848–854. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ripoll GV, Garona J, Pifano M, Farina HG,
Gomez DE and Alonso DF: Reduction of tumor angiogenesis induced by
desmopressin in a breast cancer model. Breast Cancer Res Treat.
142:9–18. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ripoll GV, Farina HG, Yoshiji H, Gomez DE
and Alonso DF: Desmopressin reduces melanoma lung metastasis in
transgenic mice overexpressing tissue inhibitor of
metalloproteinases-1. In Vivo. 20:881–885. 2006.PubMed/NCBI
|
|
28
|
Alonso DF, Skilton G, Farias EF, Bal de
Kier Joffe E and Gomez DE: Antimetastatic effect of desmopressin in
a mouse mammary tumor model. Breast Cancer Res Treat. 57:271–275.
1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Giron S, Tejera AM, Ripoll GV, Gomez DE
and Alonso DF: Desmopressin inhibits lung and lymph node metastasis
in a mouse mammary carcinoma model of surgical manipulation. J Surg
Oncol. 81:38–44. 2002.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hermo GA, Torres P, Ripoll GV, Scursoni
AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin
prolongs survival in surgically treated bitches with mammary gland
tumours: A pilot study. Vet J. 178:103–108. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hermo GA, Turic E, Angelico D, Scursoni
AM, Gomez DE, Gobello C and Alonso DF: Effect of adjuvant
perioperative desmopressin in locally advanced canine mammary
carcinoma and its relation to histologic grade. J Am Anim Hosp
Assoc. 47:21–27. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Iseas S, Roca EL, O'Connor JM, Eleta M,
Sanchez-Luceros A, Di Leo D, Tinelli M, Fara ML, Spitzer E, Demarco
IA, et al: Administration of the vasopressin analog desmopressin
for the management of bleeding in rectal cancer patients: Results
of a phase I/II trial. Invest New Drugs. 38:1580–1587.
2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nair AB and Jacob S: A simple practice
guide for dose conversion between animals and human. J Basic Clin
Pharm. 7:27–31. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ray G, Banerjee S, Saxena NK, Campbell DR,
Van Veldhuizen P and Banerjee SK: Stimulation of MCF-7 tumor
progression in athymic nude mice by 17beta-estradiol induces
WISP-2/CCN5 expression in xenografts: A novel signaling molecule in
hormonal carcinogenesis. Oncol Rep. 13:445–448. 2005.PubMed/NCBI
|
|
35
|
Pastrian MB, Guzman F, Garona J, Pifano M,
Ripoll GV, Cascone O, Ciccia GN, Albericio F, Gómez DE, Alonso DF
and Iannucci NB: Structure-activity relationship of
1-desamino-8-D-arginine vasopressin as an antiproliferative agent
on human vasopressin V2 receptor-expressing cancer cells. Mol Med
Rep. 9:2568–2572. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Carie AE and Sebti SM: A chemical biology
approach identifies a beta-2 adrenergic receptor agonist that
causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2
pathway. Oncogene. 26:3777–3788. 2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Insel PA, Zhang L, Murray F, Yokouchi H
and Zambon AC: Cyclic AMP is both a pro-apoptotic and
anti-apoptotic second messenger. Acta Physiol (Oxf). 204:277–287.
2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Naviglio S, Di Gesto D, Romano M,
Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M,
Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by
cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer
cells. Cancer Biol Ther. 8:1183–1190. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Castoria G, Migliaccio A, D'Amato L, Di
Stasio R, Ciociola A, Lombardi M, Bilancio A, Di Domenico M, de
Falco A and Auricchio F: Integrating signals between cAMP and MAPK
pathways in breast cancer. Front Biosci. 13:1318–1327.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
Narita M, Murata T, Shimizu K, Sugiyama T,
Nakagawa T, Manganiello VC and Tagawa T: Phosphodiesterase 4 in
osteoblastic osteosarcoma cells as a potential target for growth
inhibition. Anticancer Drugs. 14:377–381. 2003.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fajardo AM, Piazza GA and Tinsley HN: The
role of cyclic nucleotide signaling pathways in cancer: Targets for
prevention and treatment. Cancers (Basel). 6:436–458.
2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ripoll G, Iannucci N, Giron S, Cascone O,
Gomez D and Alonso D: Angiostatic activity of
1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in
breast cancer cells. Cancer Res. 68(295)2008.
|
|
43
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81 (Suppl 1):S24–S29.
2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Westphal JR, Van't Hullenaar R,
Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J,
Clemmensen I, Eggermont AA, Ruiter DJ and De Waal RM: Angiostatin
generation by human tumor cell lines: Involvement of plasminogen
activators. Int J Cancer. 86:760–767. 2000.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chesi R, Cazzola A, Bacci G, Borghi B,
Balladelli A and Urso G: Effect of perioperative transfusions on
survival in osteosarcoma treated by multimodal therapy. Cancer.
64:1727–1737. 1989.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Park JH, Hong SH and Jang WY: Restrictive
allogeneic blood transfusion strategy in patients with extremity
bone sarcomas. Medicine (Baltimore). 98(e18482)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Horowitz M, Neeman E, Sharon E and
Ben-Eliyahu S: Exploiting the critical perioperative period to
improve long-term cancer outcomes. Nat Rev Clin Oncol. 12:213–226.
2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Garona J and Alonso DF: Perioperative
biology in primary breast cancer: Selective targeting of
vasopressin type 2 receptor using desmopressin as a novel
therapeutic approach. Breast Cancer Res Treat. 158:597–599.
2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pantziarka P and Bouche G: Perioperative
therapies-using repurposed drugs to improve cancer surgery
outcomes. Cancer J. 25:100–105. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Garona J, Sobol NT and Alonso DF: Impact
of Perioperative blood transfusion on survival among women with
breast cancer: Potential benefits of blood-saving agent
desmopressin use during surgery. Am J Ther. 25:e569–e570.
2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Garona J, Sobol NT, Solerno LM and Alonso
DF: Potential use of desmopressin during hepatic resection for
colorectal liver metastases. J Surg Res. 237:1–2. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gottardo MF, Capobianco CS, Sidabra JE,
Garona J, Perera Y, Perea SE, Alonso DF and Farina HG: Preclinical
efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer
metastasic colonization. Sci Rep. 10(14689)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guijarro MV, Ghivizzani SC and Gibbs CP:
Animal models in osteosarcoma. Front Oncol. 4(189)2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Clezardin P, Drouin J, Morel-Kopp MC,
Hanss M, Kehrel B, Serre CM, Kaplan C and Delmas PD: Role of
platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet
alpha-granule proteins in platelet aggregation induced by human
osteosarcoma cells. Cancer Res. 53:4695–4700. 1993.PubMed/NCBI
|
